SECOND GENOME
Dead / Abandoned — Abandoned — no statement of use filed (as of 09 Jan 2023)
What this means for you
This application is over — abandoned 09 Jan 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88620543
- Mark type
- Stylized text
- Filed
- 17 Sept 2019
- Published for opposition
- 14 Apr 2020
- Abandoned
- 09 Jan 2023
- Attorney of record
- Lisa Greenwald-Swire
Goods and services
- Class 005 — Pharmaceuticals: Medical and veterinary therapeutic pharmaceutical for the treatment of metabolic, central nervous system, endocrine, musculoskeletal, cardiovascular, degenerative, neurodegenerative, oncological, neurological, gastrointestinal, developmental, hepatological, ophthalmic, respiratory, hormonal, dermatological, psychiatric, chronic inflammatory and autoimmune related diseases and disorders in humans and animals
Owner
- Second Genome, Inc., San Francisco, CA, US
- Second Genome, Inc., San Francisco, CA, US
Prosecution history
- 09 Jan 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 09 Jan 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 25 May 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 May 2022 — SOU EXTENSION 4 GRANTED
- 23 May 2022 — SOU EXTENSION 4 FILED
- 23 May 2022 — SOU TEAS EXTENSION RECEIVED
- 03 Nov 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Nov 2021 — SOU EXTENSION 3 GRANTED
- 01 Nov 2021 — SOU EXTENSION 3 FILED
- 01 Nov 2021 — SOU TEAS EXTENSION RECEIVED
- 03 Jun 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Jun 2021 — SOU EXTENSION 2 GRANTED
- 01 Jun 2021 — SOU EXTENSION 2 FILED
- 01 Jun 2021 — SOU TEAS EXTENSION RECEIVED
- 04 Dec 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED